Aeglea BioTherapeutics presented 20-dose data on 14 patients from the company's completed Phase 1/2 trial and ongoing Phase 2 open-label extension, or OLE, trial for pegzilarginase in patients with Arginase
1 Deficiency, or ARG1-D, at the Symposium of the Society for the Study of Inborn Errors of Metabolism, or SSIEM.
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE): Phase 1/2, 20-week repeat dose data for pegzilarginase in arginase
1 deficiency (Sept.
ENPNewswire-August 30, 2019--Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase
1 Deficiency at 2019 SSIEM Symposium
Newer immunomarkers of hepatocellular Differentiation, such as arginase
1 and glypican 3, have been successfully used in hepatoid carcinoma of other organs (pancreas, adrenal, lung, and stomach).
Specifically, we will investigate whether and how the inhibition of selected enzymes involved in the generation of this new metabolic checkpoint can impact on the efficacy of immunotherapeutic agents, including immune checkpoint inhibitors, arginase
inhibitors as well as adoptive therapy with car-t cells and car-nk cells.
is an important enzyme that catalyzes the conversion of arginine to ornithine and urea.
Immunohistochemical pitfalls and the importance of glypican 3 and arginase
in the diagnosis of scirrhous hepato-cellular carcinoma.
During chronic infection, arginase-expressing myeloid-derived suppressor cells and circulating arginase
increased in phase with HBV replication without immunopathology, and thus L-arginine decreased.
activity can lower NO level by reducing the substrate for NO synthase.
Increased arginine is a feature of the urea cycle disorder arginase
deficiency, but ornithine, the product of the arginase
reaction, is expected to be low to normal rather than increased as observed in this patient.
A novel and promising therapeutic approach for NSCLC: recombinant human arginase
alone or combined with autophagy inhibitor.
Additionally, the expression of the following four macrophage polarization markers transglutaminase 2 (Tgm2), arginase
1 (Arg1), chemokine (C-X-C motif) ligand 9 (Cxcl9), and nitric oxide synthase 2 (Nos2) was also assessed (example gating schema in Supplementary Figure 8).